AVXL vs. PTCT, RNA, RYTM, IMVT, MLTX, ACAD, XENE, VCEL, MOR, and SWTX
Should you be buying Anavex Life Sciences stock or one of its competitors? The main competitors of Anavex Life Sciences include PTC Therapeutics (PTCT), Avidity Biosciences (RNA), Rhythm Pharmaceuticals (RYTM), Immunovant (IMVT), MoonLake Immunotherapeutics (MLTX), ACADIA Pharmaceuticals (ACAD), Xenon Pharmaceuticals (XENE), Vericel (VCEL), MorphoSys (MOR), and SpringWorks Therapeutics (SWTX). These companies are all part of the "pharmaceutical products" industry.
Anavex Life Sciences vs.
Anavex Life Sciences (NASDAQ:AVXL) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, community ranking, analyst recommendations, valuation and risk.
31.5% of Anavex Life Sciences shares are owned by institutional investors. 11.0% of Anavex Life Sciences shares are owned by insiders. Comparatively, 5.5% of PTC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Anavex Life Sciences has higher earnings, but lower revenue than PTC Therapeutics. Anavex Life Sciences is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.
Anavex Life Sciences has a net margin of 0.00% compared to PTC Therapeutics' net margin of -50.32%. PTC Therapeutics' return on equity of 0.00% beat Anavex Life Sciences' return on equity.
Anavex Life Sciences currently has a consensus price target of $44.00, indicating a potential upside of 371.34%. PTC Therapeutics has a consensus price target of $55.00, indicating a potential upside of 25.17%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Anavex Life Sciences is more favorable than PTC Therapeutics.
PTC Therapeutics received 127 more outperform votes than Anavex Life Sciences when rated by MarketBeat users. However, 74.61% of users gave Anavex Life Sciences an outperform vote while only 61.89% of users gave PTC Therapeutics an outperform vote.
Anavex Life Sciences has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.
In the previous week, PTC Therapeutics had 2 more articles in the media than Anavex Life Sciences. MarketBeat recorded 14 mentions for PTC Therapeutics and 12 mentions for Anavex Life Sciences. PTC Therapeutics' average media sentiment score of 0.41 beat Anavex Life Sciences' score of 0.25 indicating that PTC Therapeutics is being referred to more favorably in the news media.
Summary
Anavex Life Sciences beats PTC Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Anavex Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anavex Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:AVXL) was last updated on 1/21/2025 by MarketBeat.com Staff
